Despite the rapid progress in cancer screening, diagnosis, and treatment, treatment‐related cardiovascular events such as radiation‐induced cardiac injury remain unavoidable.5 LVEF and blood markers (NT‐pro‐BNP/BNP and cTnI) are still classical methods in clinical practice for the risk assessment, diagnosis, and management of RIHD.22 In the small sample longitudinal study of cardiac biomarkers in patients receiving thoracic radiotherapy, Gomez et al23 showed that BNP increases during high‐dose irradiation of the heart in some patients. The gene discussed is TNNI3; the disease is cancer.